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Abstract	  
Research	   in	   signal	   transduction	   aims	   to	   identify	   the	   functions	   of	   different	   signaling	  
pathways	  in	  physiological	  and	  pathological	  states.	  Traditional	  techniques	  using	  biochemical,	  
genetic	   or	   cell	   biological	   approaches	   have	   made	   important	   contributions	   to	   our	  
understanding	  of	  cellular	   signaling.	  However,	   the	  single-­‐gene	  approach	  does	  not	   take	   into	  
account	   the	  whole	   complexity	  of	   cell	   signaling.	  With	   the	  availability	  of	  OMICs-­‐techniques,	  
great	  progress	  has	  been	  made	  in	  understanding	  signaling	  networks.	  OMICs	  approaches	  can	  
be	   classified	   into	   two	   categories:	   “molecular	   profiling”,	   including	   genomic-­‐,	   proteomic-­‐,	  
post-­‐translational	   modification-­‐	   and	   interactome-­‐profiling;	   and	   “molecular	   perturbation”,	  
including	  genetic	  and	  functional	  perturbations.	  	  
Due	  to	  the	  ever-­‐growing	  field	  of	  method	  development	  to	  characterize	  cellular	  processes	  
on	  genomic	  and	  proteomic	  levels	  and	  in	  many	  other	  dimensions,	  it	  has	  become	  a	  challenge	  
to	   select	   and	   apply	   the	   appropriate	  methods	   suitable	   for	   addressing	   a	   specific	   biological	  
question.	  In	  this	  perspective,	  we	  will	  describe	  some	  selected	  OMICs-­‐techniques	  and	  discuss	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Introduction	  
Cell	   signaling	   (signal	   transduction)	   relays	  extracellular	  and	   internal	   signals	   to	  different	  
cellular	   compartments,	   and	   regulates	   various	   cellular	   reactions	   in	   response	   to	  
environmental	   and	   intracellular	   changes.	   It	   plays	   essential	   roles	   in	   almost	   all	   cellular	  
functions	  and	  is	  carried	  out	  by	  multiple	  parallel	  pathways.	  	  
In	  general,	  despite	  diverse	  and	  complex	  pathways,	  signal	  transduction	  proceeds	  through	  
five	   distinct	   steps:	   (i)	   recognition	   of	   a	   signal	   –	   typically	   in	   the	   form	   of	   a	   receptor-­‐ligand	  
engagement;	  (ii)	  conversion	  of	  a	  signal	  into	  biochemical	  imprints	  such	  as	  phosphorylation	  or	  
other	   post-­‐translational	   modifications	   (PTMs);	   (iii)	   relay	   of	   a	   signal	   by	   engagement	   of	  
binding	   partners	   and	   subsequent	   transmission	   of	   information	   through	   either	   changes	   in	  
conformation	  or	  biochemical	   imprints;	   (iv)	  signal	  processing	  to	  maintain	  the	  robustness	  of	  
information	   transmission	   and	   signal	   integration	   to	   synchronize	   multiple	   signal	   inputs;	   (v)	  
conversion	  of	  the	  signal	  into	  a	  biological	  response	  such	  as	  the	  transcription	  of	  target	  genes	  
or	  the	  synthesis	  of	  proteins	  and	  metabolites	  (Fig.	  1).	  
Understanding	   each	   of	   these	   steps	   lies	   at	   the	   heart	   of	   cell	   signaling	   research	   and	  
requires	  distinct	  technologies	  in	  order	  to	  achieve	  this.	  	  
Cells	  use	  different	  mechanisms	  such	  as	  (a)	  PTMs,	  (b)	  protein-­‐protein	  interactions	  (PPIs),	  
and	  (c)	  changes	  in	  localization	  (translocation)	  to	  relay	  and	  process	  signals.	  Phosphorylation	  
is	  one	  of	  the	  most	  common	  PTMs1.	  It	  functions	  through	  inducing	  conformational	  change	  in	  a	  
target	  protein,	  or	  changing	  the	  accessibility	  between	  enzyme	  and	  interacting	  protein2.	  Such	  
mechanisms	  allow	  for	  a	  change	  of	  enzyme	  activity,	  or	  changes	  in	  interactions	  between	  host	  
proteins	  and	  other	  molecules	  and	  hence,	  provide	  a	  tuneable	  process	  for	  signal	  propagation	  
and	   termination.	   Ubiquitylation,	   sumoylation	   or	   acetylation	   are	   other	   important	   PTMs3-­‐5,	  
each	  leading	  to	  a	  very	  distinct	  response	  such	  as	  regulating	  protein	  stability,	  enzyme	  activity	  
or	  modifying	  protein-­‐protein	   interactions.	  The	  most	  common	  techniques	  to	  monitor	  PTMs	  
are	  based	  on	  mass	  spectrometry	  (MS)	  as	  outlined	  in	  more	  detail	  below.	  	  
PPIs	   are	   often	   achieved	   through	   specialized	   domains	   and	   play	   a	   crucial	   role	   in	   signal	  
transduction6,	   7.	   PPIs	   can	   regulate	   enzyme	   activity	   through	   allosteric	   effect	   or	   direct	  
interaction	  with	  active	  sites.	   Interaction	  of	  a	  protein	  with	  scaffold/adaptor	  proteins	  brings	  
signaling	   molecules	   close	   to	   each	   other,	   or	   targets	   them	   to	   the	   right	   cellular	   location.	  
Sequestering	   signaling	   molecules	   from	   other	   signaling	   components	   or	   locations	   secures	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signaling	  specificity	  and	  reduces	  signaling	  noise.	  Different	  types	  of	  PPIs	  with	  various	  physical	  
characteristics	   such	   as	   strong/weak	   and	   stable/transient	   interactions	   all	   play	   roles	   in	  
signaling	   and	   have	   different	   biological	   advantages.	   Various	   PPI-­‐assays	   amenable	   to	   large-­‐
scale	  OMICs	  measurement	  will	  be	  discussed	  below.	  
Translocation	   of	   signaling	   molecules,	   required	   for	   accurate	   and	   efficient	   signal	  
processing,	  is	  usually	  carried	  out	  by	  facilitated/active	  transportation	  machineries8.	  Changes	  
in	   localization	  are	  usually	  visualized	  by	  microscopy-­‐based	   techniques	  such	  as	  high-­‐content	  
screening.	  
Although	  most	  signaling	  pathways	  display	  features	  of	  serial	  processing,	  they	  are	  usually	  
not	   linear9.	   It	   is	   common	   for	   several	   upstream	   pathways	   to	   converge	   into	   one	   common	  
downstream	   pathway,	   or	   one	   upstream	   pathway	   to	   diverge	   into	   several	   downstream	  
pathways.	   Existence	   of	   protein	   isoforms	   or	   different	   molecules	   with	   similar	   functions	  
creates	  pathway	  redundancy.	  Signaling	  circuits	  such	  as	  feedforward-­‐	  and	  feedback-­‐loops	  are	  
also	  present	   in	  many	  pathways.	  Moreover,	  parallel	  pathways	  can	  communicate	  with	  each	  
other	   through	   lateral	   crosstalk.	   These	   features	   enable	   a	   complex,	   robust,	   and	   flexible	  
signaling	  network,	  making	  it	  resistant	  to	  signal	  noise	  but	  able	  to	  respond	  to	  environmental	  
and	  cellular	  alterations.	  Box	  1	  highlights	  some	  major	  signaling	  pathways.	  
Applying	  OMICs	  techniques	  to	  identify	  cell	  signaling	  networks	  in	  health	  and	  disease	  can	  
help	  identify	  sites	  for	  therapeutic	  intervention	  and	  define	  potential	  drug	  targets.	  In	  general,	  
OMICs	   approaches	   are	   defined	   as	   high-­‐throughput	   technologies	   that	   aim	   to	   generate	   a	  
comprehensive	   view	   of	   molecular	   cell	   components.	   They	   generally	   aim	   at	   the	   universal	  
detection	  of	  genes	  (genomics),	  mRNA	  (transcriptomics),	  proteins	  (proteomics),	  metabolites	  
(metabolomics)	  or	  lipids	  (lipidomics)	  in	  a	  specific	  biological	  sample.	  
OMICs	   approaches	   comprise	  molecular	   profiling	   techniques	   that	   allow	   the	   capture	  of	  
protein	   and	   gene	   components	   and	   their	   interactions.	   They	   are	   often	   complemented	   by	  
perturbation	   methods	   that	   probe	   the	   gain	   or	   loss	   of	   such	   components	   in	   order	   to	  
understand	  their	  functional	  role	  in	  signaling	  pathways.	  A	  third	  approach,	  the	  computational	  
reconstruction	  of	  networks,	  allows	  assessment	  of	  signal	  integration	  and	  processing10,	  11.	  	  
In	   this	  perspective,	  we	  will	  mainly	  discuss	  OMICs	  approaches	  applied	  to	  measure	  PPIs	  
and	   protein-­‐based	   cell	   signaling.	   This	   perspective	   does	   not	   aim	   to	   cover	   all	   OMICs	  
techniques;	   instead,	  we	  only	   try	   to	   introduce	   the	  more	   recently	  developed	  approaches	  as	  
well	   as	   some	   already	   existing	   techniques	   that	   had	   important	   impacts	   on	   cell	   signaling	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research.	  As	  this	  is	  a	  very	  complex	  research	  area,	  we	  recommend	  other	  review	  articles	  that	  
specifically	  cover	  other	  aspects	  of	  this	  fast	  growing	  research	  field11-­‐13.	  Many	  techniques	  are	  
now	  available	  that	  address	  a	  specific	  aspect	  in	  the	  signaling	  cascade	  and	  we	  provide	  a	  guide	  
for	   the	   reader	   to	   identify	   which	   method	   for	   profiling/perturbation	   is	   best	   suited	   for	   the	  
question	   they	   want	   to	   address	   and	   additionally,	   which	   key	   properties	   and	   intrinsic	  
limitations	  each	  approach	  has	  (Table	  1	  and	  2).	  	  
	  
Molecular	  Profiling:	  Assessing	  protein	  networks	  
Proteomic	  profiling	  based	  on	  mass	  spectrometry	  (MS)	  
MS	   is	   an	   important	   proteomics	   tool	   and	   is	  widely	   used	   for	   protein,	   PTM	  and	  protein	  
complex	   profiling	   in	   near	   genomics-­‐wide	   scales.	   For	   example,	   tandem	  affinity	   purification	  
(TAP)	   has	   achieved	   great	   success	   in	   protein	   complex	   identification14.	   An	   impressive	  
development	   is	   quantitative	   MS,	   which	   allows	   in-­‐depth	   analysis	   of	   quantitative	   traits	   of	  
signaling	  processes.	  Quantification	  can	  be	  accomplished	  through	  isotopic	  labeling	  or	  a	  label-­‐
free	  approach.	   In	  the	  first	  approach,	  stable	   isotopes	  are	   introduced	  into	  proteins/peptides	  
through	  metabolic	   labelling	   (SILAC)	   or	   direct	   chemical	   labelling	   such	   as	   ICAT	   and	   iTRAQ15	  
(Fig.	  2a).	  However,	  flaws	  include	  relatively	  narrow	  dynamic	  range	  and	  high	  expense.	  	  
A	  label-­‐free	  MS,	  selected	  reaction	  monitoring	  (SRM),	  has	  been	  used	  for	  analysis	  of	  small	  
molecules	   for	   decades	   (Fig.	   2a).	   It	   was	   adapted	   to	   quantitative	   MS	   analysis	   of	   the	  
proteome16.	   The	   instrument	   setting	   of	   SRM	   is	   composed	   of	   HPLC	   followed	   by	   triple	  
quadrupoles.	   Targeted	   peptides	   are	   selected	   by	   the	   first	   quadrupole,	   followed	   by	  
fragmentation	  in	  the	  second	  quadrupole	  and	  fragment	  selection	  in	  the	  third.	  Thus,	  the	  MS	  
signal	  intensities	  are	  recorded	  for	  each	  selected	  transition	  (precursor/fragment	  ion	  pair)	  and	  
the	   abundance	   of	   each	   precursor	   peptide	   is	   calculated	   by	   integrating	   the	   intensities	   of	  
correspondent	  ions	  to	  the	  retention	  peak.	  Several	  features	  make	  it	  an	  attractive	  method	  for	  
quantitative	   studies:	   high	   selectivity,	   high	   sensitivity	   at	   subfemtomolar	   levels,	   a	   wide	  
dynamic	  range	  with	  4-­‐5	  orders	  of	  magnitude,	  high	  reproducibility,	  and	  multiplexity.	  Multiple	  
reaction	   monitoring	   (MRM)	   indicates	   the	   same	   technology,	   but	   emphasizes	   its	   multiplex	  
capability.	  Compared	   to	  normal	   stochastic	   sampling	  MS,	  SRM	  focuses	  only	  on	  preselected	  
target	  proteins,	  and	  therefore	  favors	  hypothesis-­‐driven	  studies.	  	  SRM/MRM	  has	  successfully	  
tackled	  some	  important	  signaling	  issues,	  which	  have	  previously	  been	  difficult	  to	  address	  by	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classical	  methods.	   Recently,	   SRM/MRM	  was	   used	   to	   characterize	   the	   kinetics	   of	   receptor	  
complexes	  during	  EGFR	  signaling	  processes17,	  18.	  Nevertheless,	  assay	  development	  for	  SRM	  
is	  time-­‐	  and	  labour-­‐intensive.	  
SWATH	   is	   a	   label-­‐free	   quantitative	   MS	   method19	   (Fig.	   2a).	   It	   resembles	   SRM	   with	  
MS/MS	  settings.	  However,	  SRM	  processes	  samples	  through	  a	  data-­‐independent	  acquisition	  
(DIA)	  approach.	  In	  contrast,	  SWATH	  scans	  and	  fragments	  all	  the	  precursor	  peptides	  within	  a	  
range	  from	  the	  first	  MS.	  The	  entire	  peptide	  ions	  are	  recorded	  in	  the	  second	  MS.	  The	  target	  
peptides	  can	  be	  extracted	  with	  an	  algorithm	  similar	  to	  SRM	  by	  correlating	  them	  to	  a	  known	  
peptide	   set.	   Thus,	   SWATH	   complements	   SRM	   and	   traditional	   MS.	   On	   one	   side,	   it	   keeps	  
similar	  in-­‐depth	  features	  of	  SRM	  such	  as	  sensitivity,	  reproducibility	  and	  dynamic	  range.	  On	  
the	   other	   side,	   it	   harbors	   the	   same	   coverage	   as	   traditional	   MS.	   Furthermore,	   assay	  
development	   required	   for	   SRM	   is	   not	   necessary	   for	   SWATH.	   The	   power	   of	   SWATH	   was	  
exemplified	   by	   two	   studies	   on	   the	   dynamics	   of	   14-­‐3-­‐3	   complex20	   and	   several	   other	  
complexes21.	  	  
	  
Flow	  cytometry	  studies	  multiple	  molecular	  events	  simultaneously	  at	  the	  single	  cell	  level.	  
Traditionally,	   it	   is	   facilitated	   by	   fluorescent	   labelling.	   Nevertheless,	   fluorescent	   flow	  
cytometry	   is	   confined	   by	   the	   limitation	   of	   the	   number	   of	   fluorescent	   labellings	   due	   to	  
spectral	   overlap.	   Mass	   cytometry,	   or	   cytometry	   time-­‐of-­‐flight	   (CyTOF),	   is	   a	   new	   type	   of	  
cytometry22	   (Fig.	   2b).	   In	  contrast	  to	  fluorescent	  cytometry,	   it	  uses	  MS	  as	  readout.	  For	  this	  
purpose,	  cells	  are	  labelled	  with	  multiple	  antibodies	  tagged	  with	  different	  transition	  element	  
isotopes.	  Each	  labelled	  cell	  is	  nebulized	  and	  the	  metals	  are	  ionized.	  The	  abundance	  of	  each	  
metal	  is	  analyzed	  and	  quantified	  by	  time-­‐of-­‐flight	  MS.	  The	  striking	  feature	  of	  this	  method	  is	  
its	   considerable	   multiplexity	   derived	   from	   high	   resolution	   in	   a	   relatively	   wide	   range	   of	  
measurement.	   Theoretically,	   it	   can	   reach	   close	   to	   100	   measurements	   for	   each	   sample,	  
whereas	   practically,	   30-­‐40	  measurements	   have	   been	   achieved.	   Another	   advantage	   is	   low	  
background,	  because	  the	  tagged	  transition	  elements	  are	  usually	  absent	  in	  cells.	  In	  contrast,	  
various	   levels	   of	   autofluorescence,	   dependent	   on	   cell	   type,	   usually	   elevate	   the	   signal	  
baseline	  in	  fluorescent	  cytometry.	  Mathematical	  compensation	  is	  also	  needed	  in	  fluorescent	  
cytometry	  when	  using	  multiple	  labelling	  due	  to	  spectral	  overlap,	  which	  is	  not	  necessary	  for	  
mass	   cytometry.	   Mass	   cytometry	   produces	   a	   large	   amount	   of	   data	   and	   thereby	   needs	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extensive	  bioinformatics	  analysis.	   It	  has	  been	  successfully	  used	  in	  different	  studies	  such	  as	  
single	  cell	  characterization,	  signaling	  and	  the	  impacts	  of	  small	  molecular	  regulators23,	  24.	  
	  
Protein-­‐small	  molecule	  profiling:	  Chemoproteomics	  
Small	   molecule	   compounds	   have	   proven	   very	   useful	   to	   perturb	   or	   probe	   signal	  
transduction	  pathways	  and	  have	  the	  potential	   to	  become	  therapeutic	  agents	  as	  activators	  
or	   inhibitors	   of	   such	   pathways.	   Chemical	   proteomics,	   or	   chemoproteomics,	   studies	   such	  
protein/small	  molecule	  interaction	  at	  the	  proteomics	  level	  (Fig.	  2c)	  and	  is	  a	  combination	  of	  
both	   profiling	   and	   perturbation	   methods.	   There	   are	   two	   chemoproteomics	   approaches,	  
activity-­‐based	   protein	   profiling	   (ABPP)25	   and	   compound-­‐centric	   chemical	   proteomics	  
(CCCP)26.	  ABPP	  utilizes	   active	   site-­‐directed	  probes	   toward	  a	   specific	   enzyme	  group.	   In	   the	  
CCCP	  approach,	  bioactive	  small	  molecules	  such	  as	  drugs	  are	  immobilized	  to	  a	  solid	  matrix.	  
For	   both	   approaches,	   the	   target	   proteins	   are	   identified	   by	   quantitative	  MS.	   Compared	   to	  
traditional	   techniques,	  chemoproteomics	  excels	  with	   its	  unbiasedness	  and	  proteome-­‐wide	  
coverage.	  However,	   its	   limitations	   should	   be	   considered.	   First,	   it	   is	   difficult	   to	   immobilize	  
some	   chemicals	   without	   affecting	   their	   biological	   function.	   Second,	   some	   targets	   are	  
underrepresented	   due	   to	   their	   physical	   properties	   or	   their	   low	   abundance	   in	   cells.	   Third,	  
nonspecific	   interaction	   is	   a	   major	   challenge	   caused	   by	   abundant	   proteins	   or	   interactions	  
with	  unrelated	  parts	  of	  probes	  or	  compounds.	  Competition	  by	  pre-­‐incubation	  with	  soluble	  
compounds	   can	   partially	   overcome	   this	   problem.	   Competition	   can	   also	   be	   used	   for	   drug	  
screening,	  or	  for	  IC50	  estimation27.	  
Chemoproteomics	   is	   usually	   employed	   for	   target	   identification.	   This	   was	   perfectly	  
exemplified	  by	  a	  recent	  study28	  that	  identified	  human	  mutT	  homologue	  MTH1	  as	  the	  target	  
for	   a	   previously	  mechanistically	   elusive	   antitumor	   compound	   SCH51344.	   Since	  MTH1	   has	  
been	  previously	  demonstrated	  to	  be	  involved	  in	  preventing	  reactive	  oxygen	  species-­‐induced	  
DNA	  damage,	  this	  study	  revealed	  the	  role	  of	  DNA	  repair	  in	  the	  maintenance	  of	  cancer	  state	  
in	   some	   tumors.	   Chemoproteomics	   can	   also	   directly	   serve	   as	   a	   tool	   for	   studying	   signal	  
transduction,	   especially	   for	   characterizing	   some	   subsets	   of	   signaling	   enzymes	   such	   as	   the	  
kinome	   and	   phosphatome.	   This	   can	   be	   achieved	   by	   an	   ABPP	   approach	   using	   probes	  
targeting	   specific	   enzymes.	   For	   targets	   such	  as	   kinases,	  whose	  general	   activity	  probes	  are	  
difficult	  to	  develop,	  multiple	  kinase	  inhibitors	  have	  been	  used	  as	  affinity	  reagents	  with	  high	  
coverage	  of	   the	  kinome29.	  Using	  such	  a	  platform,	  a	   recent	  study	   investigated	  the	  dynamic	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changes	   of	   the	   kinome	   in	   response	   to	  MAPK	   pathway	   inhibition	   in	   triple-­‐negative	   breast	  
cancer	  cells	  during	  kinase	  inhibitor	  treatment30.	  
	  
Interactome	  profiling:	  PPI-­‐approaches	  
Most	   cellular	   processes,	   including	   cell	   signaling,	   rely	   on	   the	   formation	   of	   protein-­‐
complexes	  and	  the	  crosstalk	  of	  proteins	  within	  the	  same	  or	  another	  complex.	  Defining	  the	  
interaction	  patterns	  of	  proteins	  can	  give	  valuable	  insight	  into	  the	  function	  of	  a	  protein	  and	  
can	  define	  new	  drug	  targets.	  
To	  date,	  many	  interactome-­‐studies	  rely	  on	  biochemical	  MS-­‐based	  approaches31,	  which	  
directly	   address	  PPIs	   in	  protein	   complexes,	  but	   require	  extensive	  optimization	  and	  under-­‐
represent	  weak	  and	   transient	   interactions.	  An	  alternative	   is	   the	   classical	   yeast-­‐two-­‐hybrid	  
system32,	   which	   is	   a	   robust	  method	   for	  monitoring	   PPIs	   reconstituted	   in	   yeast	   cells.	   One	  
limitation	  is	  that	  interactions	  are	  forced	  to	  take	  place	  in	  the	  nucleus	  and	  many	  mammalian	  
proteins	   cannot	   be	   assayed	   in	   yeast.	   Over	   the	   years,	   a	   plethora	   of	   PPI-­‐techniques	   have	  
emerged,	  which	   led	   to	   improvement	  of	   throughput	   and	  accessibility	   to	   study	   interactions	  
that	  have	  been	  difficult	  to	  study,	  such	  as	  between	  membrane	  proteins,	  post-­‐translationally	  
modified	  proteins	  and	  transient	  interactions7.	  
The	  challenge	  of	  next-­‐generation	  PPI-­‐studies	   is	   to	  move	   from	  a	   static	   view	  of	  protein	  
complexes	  to	  a	  dynamic	  overview	  of	  proteins	  that	  change	  in	  response	  to	  various	  stimuli	  or	  
are	   deranged	   in	   diseases.	   As	  most	   aberrant	   signaling	   pathways	   are	   the	   result	   of	   network	  
rewiring,	  i.e.	  proteins	  interacting	  with	  different	  effector	  proteins,	  or	  a	  change	  in	  PTMs	  such	  
as	   phosphorylation,	   this	   stresses	   the	   need	   for	   methods	   that	   can	   probe	   PPIs	   specific	   to	  
disease-­‐states	   or	   that	   can	   be	   perturbed	   by	   drugs.	   Here,	   we	   highlight	   some	   of	   the	   PPI	  
techniques	   that	   allow	   for	   uncovering	   disease-­‐related	   interactions	   that	   occur	   in	   a	  
phosphorylation-­‐dependent	  manner,	   can	  be	  modified	  by	   various	   conditions,	   or	   that	   allow	  
for	  defining	  drug-­‐protein	  interactions.	  
	  
Genetic	   systems	   such	   as	   protein	   fragment	   complementation	   (PCA)	   assays	   and	   their	  
variants	  such	  as	  split-­‐TEV	  (Fig.	  3a)	  have	  been	  used	  to	  detect	  ligand-­‐dependent	  interactions	  
of	  ErbB	  family	  receptors,	  ligand-­‐induced	  G	  protein–coupled	  receptor	  (GPCR)	  activation	  and	  
hormone-­‐induced	   ErbB-­‐heterodimerization33-­‐35.	   The	   principle	   of	   PCAs	   exploits	   the	  
spontaneous	   folding	   of	   two	   split-­‐halves	   of	   enzymes	   once	   the	   proteins	   they	   are	   fused	   to	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interact36.	  A	  versatile	  variant	  of	  PCA	  is	  BiFC	  (bimolecular	  fluorescence	  complementation,	  Fig.	  
3a),	   which	   uses	   halves	   of	   fluorescent	   proteins	   and	   has	   been	   applied	   to	   functional	  
investigation	   of	   TGF−β and	   insulin	   signaling	   pathways37.	   It	   has	   the	   advantage	   of	   allowing	  
direct	   visualization	   of	   the	   site	   of	   protein	   interactions.	   Recently,	   the	   irreversible	   nature	   of	  
fluorescent	   PCAs	   has	   been	   overcome	   by	   the	   development	   of	   a	   novel	   PCA	   based	   on	  
Deinococcus	   radiodurans	   infrared	   protein	   IFP1.4,	   which	   has	   been	   successfully	   applied	   to	  
reconstitute	   the	   temporal	   EGF-­‐dependent	   interaction	  between	   Shc1	   and	  Grb2	   and	   allows	  
for	  detection	  of	  spatio-­‐temporal	  dynamics	  of	  PPIs,	  also	  at	  low	  abundances38.	  
	  
Another	   powerful	   PPI	   method	   is	   the	   mammalian	   protein-­‐protein	   interaction	   trap	  
(MAPPIT)	   (Fig.	   3b),	  which	   is	  based	  on	   the	  premise	   that	  a	  dysfunctional	   JAK-­‐STAT	  signaling	  
pathway	   is	   restored	   upon	   a	   specific	   bait	   and	   prey	   interaction.	   Since	   its	   development,	  
MAPPIT	  has	  been	   further	  developed	   to	  allow	   for	   identification	  of	  modification-­‐dependent	  
interactions	   (heterotrimeric	  MAPPIT)	   or	   identification	   of	   small	   molecule	   compounds	   that	  
specifically	   disrupt	   interactions	   (reverse	   MAPPIT)39,	   40.	   Another	   recently	   developed	   two-­‐
hybrid-­‐based	   method,	   which	   shares	   similarities	   with	   the	   classical	   MAPPIT	   assay,	   is	   KISS	  
(kinase	   substrate	   sensor)	   (Fig.	   3b),	   which	   allows	   for	   in	   situ	   analysis	   of	   interactions	   in	  
response	   to	   physiological	   challenges41.	   In	   KISS,	   the	   bait	   protein	   is	   fused	   to	   a	   kinase-­‐
containing	  portion	  of	  TYK2	  and	  the	  prey	  is	  coupled	  to	  a	  gp130	  cytokine	  receptor	  fragment.	  
Upon	   bait	   and	   prey	   interaction,	   TYK2	   phosphorylates	   STAT3	   docking	   sites	   on	   the	   prey	  
chimera,	   resulting	   in	   reporter	   gene	   activation.	   KISS	   has	   so	   far	   been	   applied	   to	   determine	  
external	   stimuli,	   such	   as	   agonist-­‐dependent	   interactions	   between	   GPCRs	   and	   β-­‐arrestins.	  
Furthermore,	   KISS	   allows	   for	   assaying	   pharmacological	   disruption	   of	   PPIs.	   In	   the	   three-­‐
hybrid	  KISS	   set-­‐up	   small	  molecules	   can	  be	  presented	  as	  baits	   inside	  cells	   and	  can	   thus	  be	  
assayed	  for	  their	  interaction	  with	  target	  prey	  proteins,	  which	  offers	  a	  potential	  novel	  drug-­‐
screening	  platform.	  
	  
The	  mammalian	  membrane	  two-­‐hybrid	  (MaMTH)42	  is	  a	  recently	  developed	  PCA-­‐variant	  
based	   on	   split-­‐ubiquitin	   reconstitution	   and	   is	   derived	   from	   the	   original	   membrane-­‐yeast	  
two-­‐hybrid	   system	   (MYTH)43,	   44	   (Fig.	   3c).	   It	   uses	   split-­‐halves	   of	   ubiquitin	   attached	   to	   an	  
integral	  membrane	  protein-­‐bait	  (in	  addition	  to	  a	  transcription	  factor)	  and	  a	  prey.	  Bait-­‐prey	  
interaction	   results	   in	  pseudo-­‐ubiquitin	   formation	   that	   can	  be	  cleaved	  by	  de-­‐ubiquitinating	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enzymes.	  MaMTH	  detects	   reporter	  activity	  once	  the	  transcription	   factor	  has	  been	  cleaved	  
off	   the	   bait,	   which	   only	   occurs	   if	   bait	   and	   prey	   interact.	  MaMTH	   adds	   novel	   features	   to	  
existing	   in	   vivo	   PPI-­‐techniques.	   It	   can	   be	   used	   to	   identify	   phosphorylated	   residues	   on	  
integral	   membrane	   proteins	   such	   as	   receptor	   tyrosine	   kinases	   (RTKs)	   that	   confer	  
interactions	  with	  adaptor/effector	  proteins.	  To	  date,	  phosphorylated	  sites	  of	  ErbB	  receptors	  
have	   only	   been	   detectable	   using	   MS-­‐based	   and	   anti-­‐phosphotyrosine	   antibody-­‐based	  
methods.	  MaMTH	  was	   applied	   to	   identify	   the	   increased	   activation	   state	   of	   various	   onco-­‐
genic	  ErbB	  family	  members	  via	  measurement	  of	  adaptor-­‐protein	   interaction.	  This	  adaptor-­‐
protein	  recruitment	  as	  a	  sensor	  for	  activity	  status	  of	  RTKs	  also	  allows	  for	  testing	  novel	  drugs	  
that	  can	  specifically	  inhibit	  oncogenic,	  hyperactive	  signatures	  of	  RTKs.	  
Limitations	   for	   MaMTH	   and	   MAPPIT/KISS	   are	   that	   they	   are	   reporter-­‐based	   systems.	  
Thus,	   relaying	   the	   signal	   from	   the	   site	   of	   interaction	   to	   reporter	   gene	   activation	   reflects	  
accumulation	   of	   luciferase	   over	   time,	   rather	   than	   real-­‐time	   situations.	   Amplification	   of	  
signal	  through	  the	  luciferase	  reporter	  read-­‐out	  poses	  an	  advantage,	  as	  weak	  and	  transient	  
interaction	  can	  still	  be	  assayed.	  
It	  should	  be	  kept	   in	  mind	  that	  proteins	   in	  all	  above-­‐mentioned	  approaches	  are	  mostly	  
overexpressed,	   which	   might	   be	   useful	   for	   weak	   or	   transient	   interactions,	   but	   can	   make	  
these	  assays	  prone	  to	  false	  positives.	  	  
	  
Proximity	  assays	  include	  optical	  methods	  based	  on	  resonance-­‐energy	  transfer,	  such	  as	  
between	   fluorescent	   or	   bioluminescent	   proteins	   fused	   to	   interacting	   proteins	   (FRET,	  
fluorescence	   or	   BRET,	   bioluminescence	   resonance	   energy	   transfer	   methods),	   which	   have	  
been	  widely	  used	  to	  study	  GPCR	  signaling45.	  The	  proximity	  ligation	  assay,	  PLA46	  (Fig.	  3d),	  is	  
an	   in	   situ	   method	   that	   allows	   for	   detection	   of	   PPIs,	   PTMs	   and	   protein-­‐nucleic	   acid	  
interactions	   in	   fixed	  cells	  and	   tissues.	  The	   technique	  allows	   for	  detection	  of	  proteins	  on	  a	  
single-­‐cell	  level	  and	  can	  visualize	  compartmentalization	  of	  PPIs	  in	  a	  very	  sensitive	  manner.	  
A	   pair	   of	   proximity	   probes	   (primary	   antibodies	   with	   a	   conjugated	   oligonucleotide)	  
targets	   the	  proteins	  of	   interest.	   Then,	   a	   connector	  oligonucleotide	   is	   added	  and	   connects	  
both	  proximity	  probes	  upon	  interaction	  (or	  close	  proximity)	  of	  the	  proteins.	  The	  connector	  
functions	   as	   a	   bridge	   for	   the	   enzymatic	   ligation	   reaction	   of	   the	   oligonucleotides	   on	   the	  
proximity	  probes.	  This	  produces	  a	  new	  DNA	  molecule	  that	  serves	  as	  a	  template	  for	  rolling-­‐
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circle	   amplification	   (RCA),	   replicating	   the	   DNA	  multifold,	  which	   can	   then	   be	   visualized	   by	  
attachment	  of	  fluorescent	  oligonucleotides.	  This	  results	  in	  powerful	  signal	  amplification47.	  
Multiplex	  PLA	  allows	  for	  parallel	  visualization	  of	  various	  protein	  complexes	  in	  situ48.	  This	  
improved	  PLA	  method	  can	  detect	  partners	  within	  protein	  complexes	  and	   their	   subcellular	  
localization.	   In	  situ	  PLA	  has	  been	  successfully	  applied	  to	  detect	   interactions	  between	  ErbB	  
family	  members	  and	  to	  probe	  anticancer	  drugs	  for	  their	  potential	  to	  disrupt	  ErbB	  homo-­‐	  and	  
heterodimer	  formation	  and	  to	  influence	  their	  phosphorylation	  status.	  In	  a	  recent	  study,	  PLA	  
was	   further	   developed	   to	   measure	   EGFR-­‐associated	   signaling	   complexes	   from	   patient-­‐
derived	  materials49.	   PLA	   can	  be	  used	  on	   cell	   lysates	   and	   tissue	   samples,	  which	   is	   of	   great	  
importance	   for	   clinical	   studies.	   A	   limitation	   is	   that	   the	   assay	   requires	   cell	  
permeabilization/fixing	  and	  thus	  does	  not	  reflect	  in	  vivo	  situations.	  	  
	  
Proximity-­‐dependent	  biotin	  identification	  (BioID)	  is	  an	  alternative	  approach	  to	  affinity-­‐
purification	  MS	   (AP-­‐MS)	   that	   exploits	   proximity-­‐dependent	   in	   vivo	   protein	   biotinylation50.	  
Bait	   proteins	   are	   fused	   to	   a	   promiscuous	   biotin	   ligase,	   BirA,	   which	   conjugates	   biotin	   to	  
proximal	  proteins	  in	  living	  cells.	  Interaction	  partners	  of	  BirA-­‐baits	  can	  be	  enriched	  by	  using	  
streptavidin-­‐affinity	  purification	  followed	  by	  MS-­‐analysis	  (Fig.	  3e).	  	  
Through	   combination	   of	   AP-­‐MS	   and	   BioID	   approaches	   a	   high-­‐confidence	  map	   of	   the	  
Hippo-­‐pathway	  was	  recently	  generated51.	  The	  study	  further	  showed	  that	  components	  of	  the	  
Hippo	   pathway	   are	   modulated	   by	   phosphatase	   inhibition.	   BioID	   usually	   results	   in	   larger	  
interactomes	  than	  AP-­‐MS	  analysis	  and	  allows	  for	  detection	  of	  significantly	  lower-­‐abundance	  
prey	  proteins.	  Plus,	  it	  allows	  for	  identification	  of	  interactions	  between	  chromatin-­‐associated	  
or	  membrane-­‐associated	  proteins,	  which	  is	  difficult	  to	  address	  by	  AP-­‐MS.	  	  
One	   limitation	   for	  both	  PLA	  and	  BioID	   is	   that	   they	  are	  proximity	  assays	   that	  measure	  
close	  distance	  rather	  than	  direct	  physical	  interactions.	  
	  
Molecular	  Perturbations:	  Modulating	  signaling	  events	  
Functional	  Genomics	  
Functional	   Genomics	   typically	   consists	   of	   cellular	   perturbation	   and	   subsequent	  
recording	  of	  a	  change	  in	  phenotype.	  Gene	  overexpression	  and	  knockdown	  or	  knockout	  are	  
common	  gene-­‐level	  perturbation	  strategies.	  This	  can	  be	  achieved	  by	  administration	  of	  large-­‐
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scale	   short	   interfering	   (si)	   or	   short	   hairpin	   (sh)	   RNA,	   complementary	   (c)	   DNA	   expression	  
libraries,	   peptide	   approaches	   and,	   more	   recently,	   genome	   editing	   technologies	   such	   as	  
CRISPR	   (Clustered	   Regularly	   Interspaced	   Short	   Palindromic	   Repeats)-­‐Cas9	   (CRISPR-­‐
associated	   protein	   9)52	   (Fig.	   4).	   Recording	   of	   a	   phenotype	   can	   be	   via	   biochemical	   assays,	  
reporter	  genes,	  high-­‐content	  screening	  or	  other	  OMICs	  technologies	  such	  as	  proteomic	  or	  
genomic	  profiling	  as	  discussed	  elsewhere	  in	  this	  article.	  	  
	  
Prior	   to	   the	  availability	  of	  arrayed	  cDNA	  expression	   libraries,	   so	  called	  “million	  clone”	  
libraries	  from	  cDNA	  samples	  were	  prepared	  by	  a	  number	  of	  labs.	  Such	  libraries	  have	  been	  in	  
use	  since	  the	  late	  1980s,	  but	  one	  challenge	  has	  always	  been	  over-­‐	  or	  under-­‐representation	  
of	   specific	   genes	   as	   well	   as	   missing	   estimates	   of	   coverage.	   Today,	   arrayed	   libraries	   are	  
available	  from	  a	  variety	  of	  commercial	  sources,	  although	  access	  is	  often	  limited	  due	  to	  their	  
high	  costs.	  It	  should	  be	  noted	  that	  these	  libraries	  do	  not	  take	  into	  account	  alternative	  ways	  
of	  decoding53,	  nor	  are	  they	  inclusive	  of	  all	  transcript	  variants	  and	  therefore,	  may	  represent	  a	  
cell	   type-­‐specific	   transcriptome	   rather	   than	   a	   genome-­‐wide	   coverage.	   Nonetheless,	  
expression	   cloning	   and	   arrayed	   cDNA	   expression	   have	   led	   to	   numerous	   breakthrough	  
discoveries	   such	   as	   de-­‐orphanizing	   GPCRs,	   the	   identification	   of	   tumour	   necrosis	   factor	  
receptor,	  the	  regulatory	  p85	  subunit	  of	  PI-­‐3-­‐kinase,	  the	  TYK2	  kinase	  and	  the	  identification	  of	  
multiple	   CD	   antigens,	   amongst	   others54.	   Similar	   to	   siRNA/shRNA	   experiments,	   one	   of	   the	  
challenges	   is	   delivery	   into	   cells	   that	   are	   difficult	   to	   transfect.	   Another	   problem	   is	   that	  
overexpression	   may	   lead	   to	   mislocalization	   in	   the	   cell.	   This	   can	   be	   circumvented	   by	  
validation	  of	  cDNA	  screening	  hits	  with	  complementary	  knockout	  or	  knockdown	  experiments	  
such	  as	  siRNA/shRNA	  or	  genome	  editing	  using	  zinc	  finger	  nucleases,	  TALENs	  (Transcription	  
activator-­‐like	  effector	  nucleases)	  or	  the	  CRISPR-­‐Cas9	  system.	  Furthermore,	  cDNA	  expression	  
approaches	  will	  fail	  if	  multiple	  proteins	  must	  co-­‐ordinate	  to	  achieve	  a	  function.	  Nonetheless,	  
cDNA	  expression	  screening	  is	  particularly	  powerful	  for	  the	  identification	  of	   ligand-­‐receptor	  
interactions	  and	  can	  be	  used	  for	  cell-­‐based	  protein	  interaction	  methods	  as	  discussed	  in	  the	  
previous	  section.	  	  
	  
The	   field	   of	   functional	   genomics	   has	   benefitted	   from	   two	   major	   breakthrough	  
discoveries	  made	  at	   the	  start	  of	   this	   century.	  First,	   the	  completion	  of	   the	  human	  genome	  
project	   allowed	   researchers	   to	   catalogue	  most	   coding	   (and	   non-­‐coding)	   sequences	   in	   the	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human	   genome.	   Second,	   the	   discovery	   of	   siRNAs	   and	   the	   generation	   of	   genome-­‐wide	  
knockdown	  libraries	  allowed	  for	  interrogating	  loss	  of	  function	  on	  a	  genomic	  scale.	  SiRNA	  can	  
be	   provided	   as	   synthetic	   oligonucleotides	   or	   as	   shRNA	   embedded	   in	   plasmid	   vectors.	  
Genome-­‐wide	  siRNA-­‐mediated	  knockdown	  has	  been	  successfully	  used	   in	  a	   large	  variety	  of	  
processes	  and	  has	   contributed	   to	   seminal	  discoveries	   in	   signal	   transduction,	   including	   the	  
identification	  of	   synthetic	   lethal	   interactions	  with	   the	  Ras	  oncogene55,	  novel	   regulators	  of	  
mitosis56,	   kinases	   involved	   in	   clathrin-­‐mediated	  endocytosis57	  or	  proteins	   involved	   in	  virus	  
infection58.	  	  
The	   biggest	   challenges	   in	   the	   use	   of	   siRNA/shRNA	   are	   a)	   delivery	   and	   b)	   off-­‐target	  
effects.	   Methods	   for	   delivery	   of	   siRNA/shRNA	   include	   lipofection-­‐based	   transfection,	  
electroporation	   and	   lentiviral	   transduction59,	   60.	   Most	   cell	   types	   can	   be	   transfected	  
reasonably	  well	  with	  one	  of	   these	  methods.	  Off-­‐target	  effects	  are	  more	  difficult	   to	   tackle.	  
For	   instance,	   it	   has	   been	   noted	   in	   a	   genome-­‐wide	   screen	   for	   regulators	   of	   Parkin	  
translocation	   that	   around	  30%	  of	   identified	  hits	   show	  off-­‐target	   recognition	  of	   the	  Parkin	  
kinase	   PINK161.	   In	   general,	   the	   phenomenon	   of	   off-­‐target	   effects	   has	   been	   studied	  
extensively	  and	  explained	  reasonably	  well62-­‐64,	  and	  improvements	  to	  existing	  genome-­‐wide	  
libraries	   include	   optimization	   of	   the	   siRNA	   design	   algorithms	   and	   chemistry	   of	   the	   siRNA	  
oligonucleotides	  resulting	  in	  reduced	  off-­‐target	  effects,	  as	  well	  as	  computational	  methods	  to	  
deconvolute	  false	  positives65.	  Another	  problem	  is	  reproducibility	  of	  siRNA	  screening	  results.	  
For	  example,	   in	  multiple	  HIV	  virus	   studies,	  minimal	  overlap	  of	  hit	  genes	   that	   regulate	  HIV	  
infection	   was	   noted66.	   Poor	   reproducibility	   can	   also	   arise	   from	   differences	   in	   growth	  
patterns	  of	   cells	   in	   tissue	   culture	   that	   can	  be	  overcome	  by	   computational	  methods67.	   For	  
this	  reason,	  most	  researchers	  are	  eagerly	   looking	  for	  alternative	  methods	  of	  genome-­‐wide	  
loss	   of	   function	   screening,	   for	   example	   using	   the	   recently	   developed	   CRISPR-­‐Cas9	  
technology52.	  	  
	  
Genome	   editing	   technologies	   are	   based	   on	   the	   targeted	   disruption	   of	   a	   gene	   locus,	  
most	   commonly	   through	   the	   use	   of	   endonucleases	   that	   recognize	   and	   cut	   specific	   gene	  
sequences.	  There	  are	  four	  main	  methods	  for	  genome	  editing,	  differing	  in	  the	  choice	  of	  the	  
nuclease	   and	   target	   recognition	   mode:	   zinc	   finger	   nucleases,	   TALENs,	   homing	  
meganucleases	   and	   CRISPR.	   To	   date,	   only	   the	   CRISPR-­‐Cas9	   technology	   has	   advanced	   to	   a	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stage	   where	   genome-­‐wide	   loss	   of	   function	   screening	   is	   possible,	   although	   in	   principle	  
TALENs	  may	  be	  adaptable	  to	  generate	  large-­‐scale	  libraries68.	  	  
CRISPR	   requires	   three	   components:	   tracrRNA,	   sgRNA	  and	  nuclease	  Cas9.	  The	   sequence	  of	  
the	  sgRNA	  guides	  the	  Cas9	  endonuclease	  to	  a	  specific	  site	  within	  the	  genome,	  thus	  allowing	  
site-­‐specific	  gene	  modification69.	  In	  combination	  with	  different	  Cas9	  genes,	  it	  is	  possible	  to	  
use	   CRISPR	   for	   diverse	   applications	   such	   as	   gene	   knockout,	   gene	   knockdown	   or	   gene	  
modification.	   Furthermore,	   CRISPR	   has	   recently	   been	   used	   for	   other	   approaches	   such	   as	  
chemical	   target	   identification70,	   71.	   The	   simplicity	   of	   the	   sgRNA	   sequence	   allowed	   a	   rapid	  
design	   of	   genome-­‐wide	   libraries	   using	   custom	   array	   synthesis	   and	   Gibson	   assembly.	   The	  
multiple	  libraries	  generated	  using	  this	  approach	  include	  libraries	  for	  gene-­‐knockouts,	  as	  well	  
as	  transcriptional	  activation	  or	  repression	  of	  genes72.	  	  
One	  obvious	  concern	  is	  that	  the	  sgRNA	  target	  sequence	  may	  result	  in	  off-­‐target	  effects	  
similar	  to	  those	  seen	  in	  siRNA/shRNA	  libraries73-­‐75.	  The	  level	  of	  off-­‐target	  effects	  in	  CRISPR-­‐
Cas9	   is	  not	  yet	  fully	  resolved.	  Unlike	  siRNA,	  the	  precise	  contribution	  of	  each	  nucleotide	  to	  
target	   cleavage	   is	   not	   yet	   determined	   and	   off-­‐target	   evaluations	   are	   mostly	   based	   on	  
empirical	  methods.	  	  
The	   genome-­‐wide	   libraries	   to	   date	   are	   pooled	   lentiviral	   vectors	   for	   use	   in	   positive	  
selection	  screens74,	  75.	  Pooled	  libraries	  have	  over-­‐	  and	  under-­‐representation	  of	  certain	  genes	  
that	  complicate	  genomic	  analysis.	  Hence,	  the	  generation	  of	  arrayed	  libraries	  is	  underway	  in	  
both	   academic	   labs	   and	   from	   reagent	  providers	   that	  will	   be	   important	  when	  determining	  
gene	  function	  in	  assays	  not	  amenable	  to	  positive	  selection.	  
Another	   concern	   is	   that	   knockout	   of	   genes	   using	   CRISPR	   is	   based	   on	  
insertions/deletions	   (indels)	   generated	  by	  DNA	   repair	  mechanisms	   that	   result	   in	  missense	  
frameshifting.	  Such	  indels	  will	  be	  different	  for	  each	  experiment	  and	  the	  exact	  nature	  of	  gene	  
modification	  in	  diploid	  or	  polyploid	  cell	  lines	  is	  very	  difficult	  and	  challenging	  to	  evaluate.	  In	  
this	   regard,	   the	   generation	   of	   precisely	   defined	   cell	   lines	  with	   gene	  modification	  may	   be	  
helpful,	   though	   only	   feasible	   through	   a	   concerted	   effort	   of	   a	   large	   consortium.	   There	   is	  
considerable	   development	   in	   the	   creation	   of	   mammalian	   haploid	   cell	   lines	   that	   will	  
overcome	  some	  limitations	  of	  this	  technology	  due	  to	  mixed	  genetic	  alterations	  in	  di-­‐	  or	  poly-­‐
ploid	  cell	  lines76.	  	  
	  
Genetic	  Perturbation:	  Chemical	  Genetics	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Chemical	   genetics	   is	   a	   powerful	  method	   for	  disruption	  of	   gene	  or	  protein	   function	   in	  
many	  cell	  types	  and	  even	  whole	  organisms	  such	  as	  zebrafish77,	  78.	  Strictly	  speaking,	  chemical	  
genetics	   is	   not	   a	   genomic	   or	   genetic	   method.	   It	   is	   based	   on	   the	   administration	   of	   small	  
molecule	  compounds	  that	  disrupt	  a	  genetic	  component	  of	  the	  cell.	  In	  many	  cases,	  the	  gene	  
or	   protein	   target	   of	   the	   compound	   is	   not	   known,	  making	   target	   identification	   one	   of	   the	  
biggest	  challenges.	  Efforts	  are	  underway	  to	  develop	  targeted	  chemical	  compound	  sets	  and	  
some	   commercial	   vendors	   offer	   libraries	   that	   target	   crucial	   signal	   transduction	   pathways	  
such	  as	  kinases,	  proteases	  or	  autophagy	  regulators.	  The	  use	  of	  small	  molecule	  compounds	  
has	  several	  important	  advantages79:	  first,	  the	  effect	  of	  the	  compound	  is	  much	  quicker	  than	  
that	  of	  gene	   loss,	  as	  a	  protein	  can	  be	   immediately	   inactivated.	  Thus,	  the	  method	   is	  better	  
suited	   to	   identify	   direct	   effects	   than	   indirect	   effects.	   Second,	   small	   molecule-­‐based	  
inhibition	   is	   typically	   reversible,	   allowing	   easy	   rescue	   experiments	   by	   washing	   out	   the	  
compound.	  Third,	  handling	  is	  easy,	  and	  dose	  responses	  by	  titration	  of	  the	  compound	  can	  be	  
informative	   when	   assessing	   kinetics	   of	   signal	   transduction	   pathways.	   While	   delivery	   and	  
transfection	   are	   not	   generally	   concerns,	   some	   compounds	   are	   not	   able	   to	   cross	   the	   cell	  
membrane.	  However,	  with	   improved	   library	  design,	   this	  will	   be	   solved.	   Chemical	   genetics	  
has	   been	   successfully	   used	   to	   understand	   novel	   mechanisms	   of	   cancer	   cell	   resistance	   to	  
PI3K	   inhibitors80,	   the	   identification	   of	   AMPKα2	   substrates81	   and	   the	   identification	   of	  
neuroactive	   compounds	   that	  modulate	  behavior82,	   	   to	  name	   just	   a	   few,	   and	   is	   frequently	  
used	  in	  combination	  with	  functional	  genomic	  approaches83.	  
	  
Functional	  protein	  perturbation	  
Protein	  interaction	  domains	  (PIDs)	  play	  important	  roles	  in	  the	  communication	  between	  
various	   proteins.	   One	   protein	   can	   have	   multiple	   PIDs,	   which	   poses	   a	   major	   hurdle	   to	  
specifically	  disrupt	  the	  function	  of	  one	  individual	  PID	  without	  disrupting	  the	  whole	  protein.	  
RNA	  interference	  or	  gene	  knockout	  disrupts	  the	  whole	  protein,	  and	  mutagenesis-­‐strategies	  
can	  often	  influence	  protein	  expression	  levels.	  Thus,	  protein-­‐based	  inhibitors	  are	  a	  promising	  
alternative	   to	   perform	   a	   targeted	   perturbation	   of	   PPIs.	  Multiple	  methods	   based	   on	   small	  
synthetic	  proteins	  exist,	  including	  monobodies,	  nanobodies,	  affibodies,	  stapled	  peptides	  and	  
DARPins,	   just	   to	   name	   a	   few84.	   Antibodies	   are	   the	   most	   commonly	   used	   protein-­‐based	  
inhibitors,	   but	   they	   have	   caveats	   as	   they	   are	   large	   and	   contain	   disulfide-­‐bonds,	   which	  
excludes	  them	  from	  being	  correctly	  folded	  in	  the	  reducing	  environment	  of	  the	  cytoplasm85.	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Monobodies	  offer	  an	  attractive	  alternative	  and	  allow	  for	  targeted	  PPI-­‐disruption	  at	  the	  level	  
of	   a	   single	   PID.	   Monobodies	   are	   single-­‐domain	   binding	   proteins,	   based	   on	   the	   human	  
fibronectin	  type	  III	  domain	  (FN3),	  which	  is	  a	  highly	  stable	  β-­‐sandwich	  protein85.	  They	  do	  not	  
have	  disulfides	  and	  are	  thus	  suitable	  for	  cellular	  studies.	  
Monobodies	  have	  been	  successfully	  used	  to	  disrupt	  intramolecular	  and	  intermolecular	  
interactions	   of	   Bcr-­‐Abl86.	   Constitutively	   active	   tyrosine-­‐kinase	   Bcr-­‐Abl	   causes	   chronic	  
myelogenous	   leukemia	   and	   can	   be	   successfully	   treated	  with	   the	   tyrosine	   kinase	   inhibitor	  
imatinib	   (Gleevec)87.	   Nonetheless,	   the	   appearance	   of	   secondary,	   imatinib-­‐resistance-­‐
conferring	  mutations	   in	   Bcr-­‐Abl	   poses	   a	  major	   clinical	   problem88.	   FN3-­‐based	  monobodies	  
have	   been	   shown	   to	   disrupt	   the	   SH2-­‐kinase	   domain	   interface	   of	   Bcr-­‐Abl,	   resulting	   in	  
inhibition	  of	  Bcr-­‐Abl	  activity	  through	  induction	  of	  apoptosis86.	  In	  another	  study,	  monobodies	  
were	   developed	   to	   target	   the	   SH2	   of	   the	   protein	   SHP2,	   the	   SH2-­‐domain	   containing	  
phosphatase	  2	  that	  is	  required	  for	  Bcr-­‐Abl	  dependent	  oncogenic	  transformation.	  Inhibition	  
of	   the	   SHP2-­‐SH2	  domain	  efficiently	   attenuated	   tyrosine	  phosphorylation	  and	  blocked	  ERK	  
activation89.	  There	  are	  120	  human	  SH2	  domains,	  all	  with	  a	  highly	  conserved	  phosphopeptide	  
binding	  pocket90.	  Thus,	  developing	  specific	  inhibitors	  for	  SH2	  domains	  of	  different	  proteins	  
poses	  a	  challenge	  that	  can	  be	  overcome	  by	  monobody	  development91.	  
Monobodies	   prove	  useful	   tools	   for	   the	   functional	   perturbation	  of	   signaling	   networks,	  
especially	  in	  cancer	  cells.	  As	  they	  are	  very	  specific,	  this	  allows	  selective	  disruption	  of	  any	  PID	  
without	  affecting	   the	   rest	  of	   the	   targeted	  protein.	  An	  alternative	   to	  monobodies	  are	  non-­‐
antibody	   binding	   proteins	   based	   on	   synthetic	   protein	   scaffolds	   and	   developed	   through	  
directed	  evolution	  to	  bind	  to	  a	  specific	  protein	  domain,	  thereby	  potentially	  disrupting	  PPIs92.	  	  
	  
OMICs	  –	  where	  do	  we	  go	  from	  here?	  
OMICs	   techniques	   have	   enabled	  major	   breakthroughs	   in	   the	   field	   of	   cell	   signaling,	   in	  
large	  part	  due	  to	  the	  development	  of	  specific	  assays	  capable	  of	  dissecting	  the	  distinct	  steps	  
of	   cellular	   signaling	   events.	   The	   major	   advantage	   of	   OMICs-­‐techniques	   is	   their	   ability	   to	  
uncover	  novel	  aspects	  through	  unbiased,	  large-­‐scale	  approaches,	  which	  provide	  researchers	  
with	   data	   on	   a	   previously	   unprecedented	   genome/proteome-­‐wide	   scale.	   Careful	   use	   of	  
individual	  OMICs	  techniques	   in	  complex	  with	  other	  assays,	   including	  orthogonal	  validation	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and	  bioinformatics	  analysis,	  allows	  the	  production	  of	  detailed	  high-­‐confidence	  maps	  of	  cell	  
signaling	  events.	  	  	  
One	  of	   the	  primary	  challenges	   that	   come	  with	  high-­‐throughput	   research	   is	  effectively	  
translating	   the	   vast	   amounts	   of	   accumulated	   data	   into	   meaningful	   biological	   contexts.	  
Combining	  computational	  methods	  with	  OMICs-­‐data	  is	  a	  powerful	  synergy,	  and	  can	  be	  used	  
to	   model	   and	   predict	   signaling	   events	   or	   to	   integrate	   new	   results	   with	   other	   existing	  
datasets	  to	  identify	  high-­‐fidelity	  hits	  whose	  proper	  biological	  context	  (and	  potential	  clinical	  
application)	   can	   be	   more	   clearly	   ascertained93.	   Biological	   validation	   experiments	   are	  
necessary	   to	   functionally	   confirm	   the	   identified	   candidates	   and	   characterize	   their	   roles	   in	  
cellular	  mechanisms.	  
Another	   bottleneck	   of	   large-­‐scale	   analyses	   is	   data-­‐standardization	   and	   comparability	  
among	   various	   technologies.	   While	   many	   OMICs-­‐techniques	   complement	   each	   other,	  
meaning	  that	  different	  techniques	  uncover	  different	  aspects	  of	  cell	  signaling,	  this	  also	  poses	  
a	   challenge	   for	   developing	   a	   gold	   standard	   for	   OMICs-­‐analyses,	   as	   results	   from	   different	  
approaches	   can	   often	   not	   directly	   be	   compared	  with	   each	   other.	   Standardized	   reference	  
datasets	  and	  confidence	   scores,	  as	  used	   in	  PPI-­‐interaction	  mapping,	   can	  help	  address	   this	  
difficulty,	  facilitating	  comparison	  of	  datasets	  produced	  by	  different	  techniques	  and	  aiding	  in	  
the	   identification	   of	   promising	   interactions94.	   This	   has	   recently	   been	   done	   for	   functional	  
genomics,	  where	  off-­‐target	  effects	  of	  shRNA	  and	  CRISPR	  screens	  pose	  a	  major	  limitation	  for	  
genome-­‐manipulation	  and	  where	  error	  rates	  have	  been	  difficult	  to	  assess,	  to	  evaluate	  data	  
quality	  of	  genome-­‐scale	  fitness	  screens95.	  
Recent	   years	   have	   seen	   the	   development	   of	   many	   new	   technologies	   allowing	   the	  
identification	   of	   novel	   interactors,	   phosphorylation	   sites	   and	   PTMs	   involved	   in	   signaling	  
cascades,	   as	   well	   as	   new	   tools	   to	   perturb	   signaling	   events	   on	   the	   level	   of	   genome-­‐
modification	   or	   interference	  with	   proteins.	   In	   order	   to	   improve	  OMICs	   approaches	   in	   the	  
signaling	   field,	   technologies	   will	   have	   to	   be	   developed	   to	   investigate	   transient	   and	   weak	  
interactions.	   Kinases	   and	   phosphatases	   are	   key	   regulators	   of	   signaling	   events	   and	   can	  
determine	   whether	   signaling	   is	   turned	   on	   or	   attenuated,	   however,	   kinase-­‐substrate	   and	  
phosphatase-­‐substrate	   interactions	   are	   mostly	   missing	   from	   current	   PPI-­‐datasets.	   One	  
promising	  approach	  is	  the	  yeast-­‐based	  M-­‐track	  method,	  which	  allows	  for	  detection	  of	  short-­‐
lived	   interactions96.	   This	   study	   showed	   that	   three-­‐quarters	   of	   the	   proteome	   in	   human	  
cancer	   cells	   is	   phosphorylated,	   and	   corroborated	   the	   key	   involvement	   of	   tyrosine	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phosphorylation	   in	   signaling	   cascade	   events	   by	   demonstrating	   the	   importance	   of	  
phosphotyrosine	  in	  stimulated	  relative	  to	  unstimulated	  cells97.	  
In	  the	  future,	  OMICs-­‐technologies	  will	  be	  tasked	  with	  uncovering	  the	  role	  of	  other	  post-­‐
translational	   modifications	   in	   signaling	   events1,	   such	   as	   ubiquitylation,	   sumoylation	   and	  
glycosylation,	  requiring	  the	  development	  of	  new	  assays	  that	  can	  detect	  those	  modifications	  
in	  a	  fast	  and	  cost-­‐effective	  manner.	  Overall,	  OMICs-­‐technologies	  represent	  powerful	  tools	  to	  
uncover	  networks	  of	  signaling	  events	  and	  to	  perturb	  signaling	  cascades.	  In	  combination	  with	  
orthogonal	   validation	   methods,	   in-­‐depth	   bioinformatics	   analyses	   and	   careful	   functional	  
studies,	   data	   generated	   by	   OMICs-­‐techniques	   will	   help	   answer	   fundamental	   biological	  
questions	  and	  define	  novel	  targets	  of	  therapeutic	  relevance	  to	  human	  health.	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Figure	  Legends	  
Figure	  1.	  Overview	  of	  signal	  transduction	  cascades.	  
Signal	  transduction	  follows	  a	  general	  principle,	  which	  includes	  five	  steps	  to	  convert	  an	  input	  
signal,	   such	   as	   receptor-­‐ligand-­‐binding,	   into	   an	   output	   signal	   like	   the	   biochemical	   and	  
genetic	  alteration	  of	  a	  cell.	  
Signal	   recognition	   typically	   takes	   place	   at	   the	   cell	   surface	   (step	   1).	   The	   signal	   has	   to	   be	  
transferred	  into	  the	  cell	  without	  the	  molecule	  itself	  entering.	  A	  receptor	  often	  performs	  the	  
function	   of	   information	   transfer	   across	   the	   membrane	   by	   binding	   to	   a	   ligand.	   Once	  
receptor-­‐ligand	  binding	   takes	  place,	   this	   leads	   to	   conformational	   changes	  of	   the	   receptor,	  
which	   leads	   to	   activation	   of	   the	   receptor,	   when	   the	   receptor	   itself	   is	   an	   enzyme,	   or	  
modification	  of	   the	  activities	  of	   recruited	  enzymes.	  As	   chemical	   imprints	  and	  major	   signal	  
carriers,	   PTMs	   such	   as	   phosphorylation	   are	   carried	   out	   by	   receptors	   or	   a	   series	   of	  
downstream	   enzymes	   (step	   2).	   Signal	   processing	   is	   also	   facilitated	   by	   binary	   PPI,	   protein	  
complex	  formation,	  or	  signaling	  protein	  translocation	  to	  sites	  such	  as	  the	  nucleus.	  Multiple	  
input	  signals	  can	  be	  synchronized	  and	  processed	  to	  generate	  a	  signal	  response	  (steps	  3	  and	  
4).	   Final	   biological	   outcomes	   are	   achieved	   by	   modification	   of	   different	   intracellular	  
machineries	  such	  as	  transcription	  and	  translation	  (step	  5).	  
Each	   of	   the	   individual	   five	   steps	   of	   signal	   transduction	   can	   be	   dissected	   into	   various	  
branches,	   depending	   of	   what	   components	   are	   known	   and	   which	   information	   is	   needed.	  
Profiling	  methods	  aim	  to	  gain	  information	  about	  the	  network	  surrounding	  a	  certain	  signaling	  
component,	  whereas	  perturbation	  methods	  aim	  to	  disrupt	  signaling	  networks	  on	  proteomic	  
or	  genomic	  levels	  in	  order	  to	  identify	  their	  functional	  role.	  	  
	  
Figure	  2.	  Molecular	  profiling	  by	  MS-­‐based	  proteomics	  methods.	  
a)	   SRM	   (MRM)	   and	   SWATH.	   In	   SRM,	   digested	   peptides	   are	   separated	   by	   liquid	  
chromatography.	   The	   targeted	   peptides	   are	   selected	   by	   the	   first	   quadrupole.	   They	   are	  
fragmented	   in	   the	   second	  quadrupole	   and	   the	   consequent	   fragments	   are	   selected	  by	   the	  
third.	  The	  peptides	  are	  quantified	  by	  integrating	  the	  intensities	  of	  corresponding	  ions	  to	  the	  
retention	   peak.	   In	   contrast,	   in	   the	   SWATH	   mode,	   all	   possible	   peptides	   in	   a	   range	   are	  
selected	   and	   recorded.	   Targeted	   proteins/peptides	   are	   selected	   and	   analyzed	   during	   the	  
stage	  of	  data	  analysis.	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b)	  Mass	   cytometry.	   The	   cells	   are	   labelled	  with	   antibodies	   tagged	  with	  different	   transition	  
element	   isotopes.	   Single	   cells	   are	   separated	   by	   a	   nebulizer	   and	   each	   tagged	   isotope	   is	  
analyzed	  by	  time-­‐of-­‐flight	  MS.	  The	  abundance	  of	  each	  element	  in	  each	  cell	  is	  recorded	  and	  
the	  whole	  set	  of	  data	  is	  then	  processed	  by	  bioinformatics-­‐analysis.	  
c)	  Chemoproteomics.	  This	  method	  is	  based	  on	  chemical	  probes,	  either	  activity-­‐based	  probe	  
(ABP)	   (in	   the	   ABPP	   approach)	   or	   small	   compounds	   (CCCP	   approach).	   The	   probes	   can	   be	  
conjugated	   to	   a	   fluorescent	   group,	   which	   can	   be	   resolved	   in	   a	   gel.	  More	   commonly,	   the	  
target	  proteins	  are	  enriched	  by	  conjugating	  the	  probe	  to	  solid	  phase	  and	  are	  then	  subjected	  
to	  MS	  analysis.	  Pre-­‐incubation	  of	  various	  compounds	  with	  lysates	  followed	  by	  quantitative	  
MS	  allows	  characterizing	  the	  dynamic	  feature	  of	  protein-­‐compound	  interaction	  such	  as	  the	  
IC50.	  
	  
Figure	  3.	  Molecular	  profiling	  using	  PPI-­‐approaches.	  
a)	  PCA.	  A	   reporter	  enzyme	   is	   split	   into	   two	  halves	   (F1	  and	  F2)	  and	   fused	   to	  bait	  and	  prey	  
proteins.	   Upon	   interaction	   the	   reporter	   enzyme	   is	   reconstituted,	   resulting	   in	   enzymatic	  
conversion	  of	  a	  substrate	  into	  a	  detectable	  product.	  In	  split-­‐TEV,	  interaction	  reconstitutes	  a	  
tobacco	   etch	   virus	   (TEV)	   protease,	   which	   cleaves	   at	   TEV	   recognition	   sites,	   releasing	   a	  
transcription	   factor	   (TF),	   which	   subsequently	   activates	   reporter	   gene	   expression.	   In	  
bimolecular	   fluorescence	   complementation	   (BiFC)	   assays,	   a	   bait-­‐prey	   interaction	  
complements	  a	  fluorescent	  protein.	  
b)	   MAPPIT.	   A	   bait-­‐protein	   is	   coupled	   to	   a	   signal-­‐deficient	   cytokine	   receptor,	   which	   lacks	  
STAT-­‐recruitment	   sites	   but	   can	   recruit	   JAKs.	   The	   prey	   is	   tethered	   to	   another	   receptor-­‐
moiety	   harboring	   STAT-­‐recruitment	   sites.	   Bait–prey	   interaction	   reconstitute	   a	   functional	  
receptor.	   Ligand-­‐binding	   leads	   to	   cross	   phosphorylation	  of	   JAKs,	  which	  phosphorylate	   the	  
prey	  receptor-­‐fragment,	  rendering	  the	  receptor	  accessible	  to	  STAT-­‐docking.	  Recruited	  STATs	  
are	   phosphorylated	   by	   JAKs,	   dimerize	   and	   enter	   the	   nucleus	   to	   activate	   reporter	   gene	  
expression.	  
KISS.	  The	  bait	   is	  fused	  to	  a	  kinase-­‐containing	  portion	  of	  TYK2,	  the	  prey	  is	  fused	  to	  a	  gp130	  
cytokine	   receptor	   fragment.	   Upon	   bait	   and	   prey	   interaction,	   TYK2	   phosphorylates	   STAT3	  
docking	  sites	  on	  the	  prey	  chimera,	  resulting	  in	  reporter	  gene	  activation.	  
c)	  MaMTH.	  An	  integral	  membrane-­‐bait	  is	  tagged	  with	  C-­‐terminal	  half	  of	  ubiquitin	  (Cub)	  and	  
a	   TF,	   and	   the	   prey	   is	   fused	   to	   N-­‐terminal	   half	   of	   ubiquitin	   (Nub).	   Upon	   bait	   and	   prey	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interaction,	   ubiquitin	   reconstitution	   occurs,	   resulting	   in	   cleavage	   by	   deubiquitinating	  
enzymes	  (DUBs)	  and	  release	  of	  the	  TF,	  which	  activates	  the	  luciferase	  reporter.	  	  
d)	  PLA.	  Two	  proximity	  probes	  are	  targeted	  to	  two	  proteins	  and	  the	  oligonucleotides	  on	  the	  
proximity	   probes	   are	   brought	   close	   together.	   These	   antibody-­‐conjugated	   oligonucleotides	  
can	  hybridize	   to	   two	   connector	  oligonucleotides	   that	   are	   ligated	  and	   form	  a	   circular	  DNA	  
molecule,	   which	   is	   amplified	   by	   rolling	   circle	   amplification	   (RCA).	   The	   resulting	   single-­‐
stranded	   DNA-­‐molecule	   is	   detectable	   through	   hybridization	   of	   fluorescently	   labeled	  
complementary	  oligonucleotides.	  
e)	   BioID.	   The	  bait	   is	   coupled	   to	   a	   promiscuous	  biotin	   protein	   ligase	  harboring	   a	  mutation	  
(BirA*).	  BirA*	  can	  catalyze	  the	  formation	  of	  activated	  biotin	  and	  dissociates	  quickly	  from	  the	  
intermediate.	   The	   BirA*-­‐tagged	   bait	   generates	   an	   activated	   biotin-­‐cloud	   in	   vivo,	   which	  
reacts	  with	  free	  primary	  amines	  of	  lysine	  residues.	  Interaction	  partners	  of	  BirA*-­‐baits	  can	  be	  
enriched	  by	  streptavidin-­‐purification	  coupled	  to	  MS	  analysis.	  	  
Figure	  4.	  Molecular	  perturbation	  methods.	  
a)	  Genomic	  perturbations.	  CRISPR-­‐technologies	  allow	  modifications	  on	  gene/genome-­‐levels.	  
Genes	   can	   be	   endogenously	   tagged	   or	   knocked	   out	   or	   mutated	   and	   modified.	   Chemical	  
genetics	   also	   allow	   modifications/disruptions	   of	   genes	   through	   application	   of	   small-­‐
molecule	  compounds.	  Whereas	  CRISPR	  allows	  for	  targeted	  gene-­‐modification,	  gene-­‐targets	  
of	  chemical	  compounds	  are	  often	  random	  and	  cannot	  be	  selected.	  
siRNA/shRNA	   technologies	   target	   mRNAs	   of	   specific	   genes,	   consequently	   leading	   to	  
reduction	   or	   disruption	   of	   protein	   expression.	   	   Targeted	   protein	   overexpression	   can	   be	  
achieved	  through	  expression	  of	  arrayed	  cDNA	  libraries.	  
b)	   Proteomic	   perturbations.	   Direct	   targeting	   of	   candidate	   proteins	   can	   be	   achieved	   by	  
applying	  chemical	  genetics-­‐screens	  and	  monobodies.	  Chemical	  compounds	  can	  directly	  bind	  
to	   proteins	   and	   lead	   to	   disruption	   of	   interactions	   with	   other	   proteins	   or	   loss	   of	   protein	  
activity.	  Whereas	  monobodies	  also	  lead	  to	  PPI-­‐disruption	  and	  loss	  of	  protein	  function,	  they	  
are	  very	  specific	  and	  can	  be	  targeted	  towards	  specific	  protein	  domains.	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Box	  1.	  Cell	  signaling	  in	  a	  nutshell	  	  
Intracellular	  signal	  transduction	  is	  carried	  out	  by	  multiple	  parallel	  signaling	  pathways.	  It	  
is	  usually	  initiated	  by	  receptors	  to	  extracellular	  or	  internal	  signals.	  Receptor	  tyrosine	  kinases	  
(RTK)	   are	   receptors	   for	   many	   growth	   factors,	   peptide	   hormones	   and	   cytokines98.	   Upon	  
engagement	  with	  their	  ligands,	  RTKs	  undergo	  dimerization,	  leading	  to	  subsequent	  activation	  
of	   the	   intracellular	   tyrosine	   kinase	  domains.	   The	  activated	  kinases	  phosphorylate	   tyrosine	  
residues,	   which	   then	   recruit	   proteins	   through	   their	   SH2	   or	   PTB	   domains.	   The	   recruited	  
proteins	   can	   be	   enzymes	   or	   scaffold	   proteins,	   which	   relay	   the	   signals	   to	   downstream	  
pathways	   such	   as	   Ras/ERK	   and	   PI3K/Akt	   pathways	   by	   mechanisms	   including	  
phosphorylation,	  PPIs/dissociation,	  and	  molecule	   translocation.	  The	  signaling	  events	  occur	  
proximal	   to	   RTKs,	   or	   in	   distal	   cellular	   compartments	   such	   as	   the	   nucleus.	   In	   the	   nucleus,	  
subsequent	   changes	   in	   transcription	   and	   epigenetic	   modification	   lead	   to	   alterations	   in	  
cellular	  outcomes	  such	  as	  proliferation,	  growth,	  survival,	  differentiation	  and	  more.	  	  
In	  contrast	  to	  RTKs,	  GPCRs	  do	  not	  have	  any	  enzymatic	  activity99.	  Binding	  to	  their	  agonists	  
induces	   a	   conformational	   change	   that	   allows	   GTP-­‐loading	   to	   heterotrimeric	   G	   proteins.	  
Subsequently,	  the	  α-­‐subunit	  binds	  and	  activates	  various	  effectors	  such	  as	  enzymes	  and	  ion	  
channels.	   The	  βγ-­‐subunits	   dissociate	   from	  α	   and	   act	   on	  other	   effectors.	   The	  outcomes	  of	  
GPCR	  signaling	  are	  very	  diverse.	  GPCRs	  can	  be	  phosphorylated	  by	  GRK	  upon	  stimulation.	  β-­‐
arrestin	   is	   recruited	   to	   phosphorylated	   receptors	   and	   regulates	   GPCR	   internalization	   and	  
degradation/recycling.	  Interestingly,	  β-­‐arrestin	  also	  activates	  MAPK	  pathways.	  	  
Another	   unique	   class	   of	   signaling	   pathways	   is	   involved	   in	   innate	   immunity	   and	  
inflammation100,	   and	   is	   initiated	   by	   receptors	   such	   as	   Toll-­‐like-­‐receptors	   (TLRs),	   Rig-­‐I-­‐like	  
receptors	  (RLRs)	  and	  Nod-­‐like	  receptors	  (NLRs),	  which	  respond	  to	  extracellular	  or	  intruding	  
pathogen	   molecules,	   or	   the	   tumor-­‐necrosis-­‐factor-­‐receptor	   (TNFR1),	   which	   responds	   to	  
cytokines	   such	   as	   TNF.	   Binding	   to	   these	  molecules	   triggers	   the	   formation	   of	   intracellular	  
complexes,	  including	  adaptor	  proteins	  and	  enzymes	  around	  the	  receptors,	  and	  finally	  leads	  
to	  activation	  of	  NFκB	  pathway	  and	  MAPK	  pathways.	  Subsequent	   transcriptional	  activation	  
produces	  a	  variety	  of	  inflammation	  mediators.	  These	  pathways	  are	  also	  crucial	  regulators	  of	  
cell	  death.	  TNFR1	  induces	  apoptosis	  through	  a	  series	  of	  caspase-­‐mediated	  proteolysis-­‐steps,	  
and	  most	  of	  these	  receptors	  control	  necroptosis	  through	  RIPK1,	  RIPK3	  and	  the	  downstream	  
regulator	   MLKL.	   The	   full	   picture	   of	   necroptosis	   is	   still	   largely	   unknown.	   The	   exact	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mechanisms	   of	   switching	   between	   inflammatory	   reaction,	   apoptosis	   and	   necroptosis	   also	  
remain	  fragmental.	  Beside	  the	  above	  three	  examples,	  many	  other	  signaling	  pathways	  such	  
as	  Wnt/βcatenin,	  TGFβ,	  Notch,	  Hedgehog,	  Hippo/MST	  pathways,	  also	  play	  diverse	  roles	   in	  
various	  cellular	  processes.	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Table	  1.	  Molecular	  profiling	  approaches	  and	  their	  key	  properties	  and	  limitations.	  
Method	   Key	  properties	   Limitations	  
SILAC	   Simple	  labelling	  and	  fast	  quantitative	  mass	  spectrometry.	   Limited	  to	  only	  living	  cells.	  
ICAT	  and	  iTRAQ	   Different	  biological	  samples	  can	  be	  labelled.	   Extra	  labelling	  step	  is	  needed.	  
SRM/MRM	   High	  sensitivity,	  accuracy	  and	  reproducibility.	   Only	  limited	  to	  targeted	  studies.	  Assay	  development	  is	  needed.	  
SWATH	   Suitable	  for	  discovery	  study	  with	  wide	  proteome	  coverage.	  
With	  similar	  sensitivity,	  reproducibility	  and	  dynamic	  range	  as	  
SRM/MRM.	  
Highly	  dependent	  on	  computation.	  
Mass	  cytometry	   Single	  cell	  measurement.	  High	  multiplexity,	  low	  background,	  
and	  no	  spectral	  overlap	  compared	  to	  fluorescent	  cytometry.	  
Antibody	  labelling	  is	  required.	  Cannot	  sort	  the	  cells.	  
Chemoproteomics	   Unbiased	  and	  proteome-­‐wide	  study	  of	  protein-­‐small	  molecule	  
interaction.	  Potential	  for	  target	  identification.	  
Chemistry	  of	  immobilizing	  probes	  may	  affect	  the	  interaction.	  
High	  background,	  and	  some	  interactions	  may	  be	  
underrepresented.	  
PPI-­‐profiling	  methods	  
PCA	   Live-­‐cell	  assay.	  Fluorescent	  PCAs	  allow	  for	  visualization	  of	  site	  
of	  interaction.	  	  Wide	  range	  of	  split-­‐PCAs	  available	  
(fluorophores,	  luciferase,	  TEV-­‐protease,	  β-­‐lactamase,	  etc.).	  
Most	  PCAs	  are	  irreversible,	  except	  infrared	  split-­‐IFP.	  
Overexpression	  artefacts	  possible.	  
MAPPIT/KISS	   Signal	  amplification	  through	  additional	  reporter	  readout	  (weak	  
and	  transient	  interactions	  can	  be	  detected).	  Live-­‐cell	  assay,	  
amenable	  to	  large-­‐scale	  applications.	  KISS	  is	  compatible	  with	  
full-­‐length	  transmembrane	  proteins.	  	  
Overexpression	  artefacts.	  Indirect	  reporter	  readout	  excludes	  
spatial	  and	  temporal	  PPI-­‐analysis.	  The	  MAPPIT-­‐interaction	  
sensor	  is	  localized	  to	  the	  plasma	  membrane,	  thus	  excluding	  PPI	  
analysis	  at	  their	  native	  localization.	  MAPPIT	  is	  incompatible	  with	  
full-­‐length	  transmembrane	  proteins.	  
MaMTH	   Designed	  for	  assaying	  full-­‐length	  integral	  membrane	  protein	  
interactions.	  Live-­‐cell	  assay,	  can	  detect	  phosphorylation-­‐
dependent	  interactions	  and	  can	  map	  phospho-­‐sites.	  Signal	  
amplification	  through	  additional	  reporter	  readout.	  
Overexpression	  artefacts	  possible	  (though	  lentiviral	  expression	  
plasmid	  are	  available).	  Luciferase-­‐readout	  only	  allows	  for	  
arrayed	  interaction	  screen,	  no	  pooled	  screening	  yet	  possible.	  As	  
for	  MAPPIT/KISS,	  indirect	  reporter	  readout	  excludes	  spatial	  and	  
temporal	  PPI-­‐analysis.	  
PLA	   In	  situ	  assay.	  Allows	  for	  detection	  of	  PPIs	  in	  fixed	  cells	  and	  
tissues.	  Can	  localize	  site	  of	  interaction.	  
Permeabilization	  or	  fixing	  is	  required.	  Proximity	  assay,	  which	  can	  
detect	  adjacent	  proteins	  that	  might	  not	  be	  true	  interactors.	  
BioID	   Can	  detect	  low	  abundant	  proteins	  (in	  contrast	  to	  conventional	  
AP-­‐MS).	  
Proximity	  assay	  can	  also	  detect	  adjacent	  proteins	  that	  might	  not	  
be	  true	  interactors.	  	  	  
Table	  2.	  Molecular	  perturbation	  approaches	  and	  their	  key	  properties	  and	  limitations.	  
	  
Method	   Key	  properties	   Limitations	  
cDNA	  libraries	   Fast	  and	  high-­‐throughput-­‐amenable	  screening	  of	  
overexpressed	  proteins.	  Full-­‐length	  arrayed	  libraries	  are	  
available	  from	  commercial	  vendors.	  	  
Overexpression	  artefacts.	  Classical	  cDNA	  libraries	  rarely	  contain	  
full-­‐length	  cDNAs,	  whereas	  commercially	  available,	  arrayed	  
libraries	  often	  miss	  transcript	  variants.	  
siRNA/shRNA	   Complements	  cDNA	  library	  screen.	  Fast	  and	  high-­‐
throughput-­‐amenable	  screening	  of	  genome-­‐wide	  
knockdowns.	  Suitable	  for	  arrayed	  and	  pooled	  screens.	  
Off-­‐target	  effects.	  Variable	  knockdown	  efficiencies.	  May	  fail	  in	  
case	  of	  functionally	  redundant	  targets.	  	  
CRISPR	   Knockout,	  knock-­‐in	  and	  endogenous	  tagging	  possible.	  
Activating	  or	  silencing	  possible.	  
Off-­‐target	  effects	  remain	  to	  be	  evaluated.	  Limited	  (pooled)	  
libraries	  available	  so	  far.	  May	  fail	  in	  case	  of	  functionally	  
redundant	  targets.	  Knockout	  of	  essential	  genes	  can	  obscure	  
functional	  readouts.	  
Chemical	  genetics	   Small	  molecule	  compounds	  targeting	  a	  certain	  gene/protein	  
in	  a	  reversible	  manner.	  Faster	  than	  si/shRNA	  knockdown	  or	  
CRISPR	  knockout,	  as	  gene	  product	  can	  be	  directly	  targeted.	  	  
Some	  compounds	  cannot	  be	  delivered	  inside	  the	  cell.	  Problem	  
of	  specificity.	  Often,	  cellular	  targets	  of	  the	  compounds	  are	  not	  




Monobodies	  offer	  targeted	  disruption	  of	  domains	  
mediating	  PPIs.	  No	  disulphide	  bonds	  allow	  use	  of	  
monobodies	  in	  cellular	  studies	  in	  contrast	  to	  antibodies.	  
Relatively	  low-­‐throughput.	  Time-­‐	  and	  cost-­‐consuming	  to	  
develop	  reagents.	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5.	  Cellular	  response	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